|
|
|
|
|
HIGHLIGHTS FROM THE 2024 EUROPEAN ASSOCIATION OF UROLOGY ANNUAL MEETING |
|
|
|
|
|
Surgical, Non-Surgical and Systemic Treatment of Localised Muscle-Invasive Bladder Cancer
|
|
| First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab Nab-Paclitaxel Followed by Postsurgical Adjuvant Nivolumab in Patients with Muscle-Invasive Bladder Cancer |
| Chiara Mercinelli, MD |
| Chiara Mercinelli presented the initial findings of the NURE-Combo trial at EAU 2024, evaluating neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC) patients. Of the 31 enrolled patients, 39% achieved a pathologic complete response, and 73.3% achieved a ≤ypT1N0 response. No disease progression occurred during neoadjuvant treatment, and the 12-month event-free survival rate was 89%. |
|
|
|
|
|
|
NMIBC: From Diagnosis to Prognosis
|
|
| A Prospective, Comparative, Within-Patient Controlled Multicenter Phase III Study Comparing Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern HD 4K Equipment |
| Hailong Hu, Ph.D. |
| Hailong Hu presented findings from a phase III trial comparing blue light cystoscopy with HAL to white light cystoscopy for bladder cancer detection using modern high-definition 4K equipment. In the study involving 158 patients, HAL BLC detected lesions not seen with WLC in 43.3% of cases, with a particularly high sensitivity for detecting CIS lesions, which were found exclusively by HAL BLC in 85% of CIS patients. |
|
|
|
|
|
| Photodynamic Diagnosis-Directed Biopsies vs White Light Bladder Mapping in Patients with Positive Cytology and Negative Preoperative Workup: An International Multicenter Retrospective Study |
| Fulvia Colucci, MD |
| Fulvia Colucci presented findings from a multicenter retrospective study comparing photodynamic diagnosis-guided biopsies to white light bladder mapping in patients with positive cytology and negative preoperative workup for bladder cancer. The study included 149 patients who underwent PDD-guided biopsies and 126 who received WL bladder mapping. Bladder CIS was detected in 14% of the PDD group and 9% of the WL group, with no significant difference in sensitivity between the two modalities. |
|
|
|
|
|
|
|
|
|
|
|
Plenary Session: Living with Advanced Kidney Cancer and Urothelial Cancer
|
|
| State-of-the-Art Lecture: Advancements in Cutting-Edge SBRT Therapy for Oligometastatic Kidney Cancer |
| Shankar Siva, PhD, MBBS, FRANZCR |
| Shankar Siva presented advancements in stereotactic ablative radiation therapy (SBRT) for oligometastatic kidney cancer at the EAU 2024 congress. Despite classical teachings of renal cell carcinoma (RCC) being radioresistant, SBRT has shown efficacy in metastatic RCC, particularly in combination with immunotherapy. |
|
|
|
|
|
|
Rapid-Fire Debates: Kidney Cancer
|
|
| Adjuvant Immunotherapy After pT3a F IV /N0 at Nephrectomy: Is That Real High-Risk for All? Yes |
| Tom Powles, MBBS, MRCP, MD |
| Thomas Powles presented at the EAU 2024 congress advocating for the use of adjuvant immunotherapy in all pT3a grade IV/N0 patients after nephrectomy based on findings from the KEYNOTE-564 study. The study demonstrated a significant improvement in overall survival with pembrolizumab compared to placebo in high-risk RCC patients. Despite the promising results, Dr. Powles highlighted the need for caution and consideration of potential toxicities. |
|
|
|
|
|
| Adjuvant Immunotherapy After pT3a F IV /N0 at Nephrectomy: Is That Real High-Risk for All? No |
| Laurence Albiges, MD, Ph.D. |
| Laurence Albiges presented at the EAU 2024 congress arguing against the use of adjuvant immunotherapy in all pT3a grade IV/N0 patients after nephrectomy. She emphasized the heterogeneity in outcomes among pT3a patients and the need for improved risk assessment, suggesting opportunities for artificial intelligence and biomarker assessments. |
|
|
|
|
|
| Does Scalpel Play a Role in Intermediate Risk Metastatic RCC? Upfront CN |
| Charles-Karim Bensalah, MD, Ph.D. |
| Charles-Karim Bensalah presented at the EAU 2024 congress arguing for the role of upfront cytoreductive nephrectomy in intermediate-risk metastatic RCC. He highlighted contemporary studies in the immunotherapy era suggesting that upfront cytoreductive nephrectomy could impact survival in selected patients. These studies, including one utilizing the Flatiron Health database and another using the IMDC database, showed improved overall survival among patients undergoing cytoreductive nephrectomy. |
|
|
|
|
|
| Does Scalpel Play a Role in Intermediate Risk Metastatic RCC? dCN |
| Axel Bex, MD, Ph.D. |
| Axel Bex argued in favor of delayed cytoreductive nephrectomy for intermediate-risk metastatic RCC patients during a presentation at the EAU 2024 congress. He emphasized the importance of accurately assessing the patient's risk status and challenged whether all intermediate-risk patients truly require systemic therapy within a year. Dr. Bex highlighted studies suggesting that observation after cytoreductive nephrectomy is safe in some cases, with a delay in progression and initiation of targeted therapy. |
|
|
|
|
|
|
